DAE HWA PHARM Co., Ltd.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. carries a market capitalization of 253.67B, placing it among publicly traded companies globally. Its enterprise value stands at 349.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. has 17.90M shares outstanding.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. trades at a trailing price-to-earnings ratio of 137.15. The price-to-sales ratio is 1.74, and the price-to-book ratio stands at 3.17.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. trades at an EV/EBITDA multiple of 40.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 140.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 349.47B versus a market cap of 253.67B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 119.07, indicating elevated leverage, while an interest coverage ratio of 1.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, DAE HWA PHARM Co., Ltd. posted a return on equity (ROE) of 2.43, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.71 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.86, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.08, useful for judging operating efficiency across full business cycles. The company generates approximately 390.80M in revenue per employee across its workforce of 367.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.92 indicates how many times DAE HWA PHARM Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, DAE HWA PHARM Co., Ltd. recorded 2.31B in income tax expense. That works out to an effective tax rate of 49.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.67B, leaving 1.82B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, DAE HWA PHARM Co., Ltd.'s stock has declined approximately 35.89% over the past 52 weeks. The 50-day moving average sits at 10,957.80, while the 200-day moving average is 12,761.05.

Over the twelve months ended March 31, 2026, DAE HWA PHARM Co., Ltd. generated 143.42B in revenue and converted that into 1.82B in net income, yielding earnings per share of 133.93. EBITDA reached 8.73B, while operating income came in at 2.49B.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. holds 10.53B in cash and equivalents against 101.28B in total debt, resulting in a net debt position of 95.50B. Total book value stands at 80.01B, with working capital of -58.27B providing operational flexibility.

DAE HWA PHARM Co., Ltd. produced 1.26B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4.37B in capital expenditures, free cash flow totaled -3.11B - equivalent to -176.28 per share.

Over the twelve months ended March 31, 2026, DAE HWA PHARM Co., Ltd. posted a gross margin of 33.90, reflecting its pricing power and cost economics. The operating margin of 1.73 and net profit margin of 1.27 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, DAE HWA PHARM Co., Ltd. paid dividends of 49.67 per share. The dividend payout ratio of 30.19 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.20, meaning DAE HWA PHARM Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, DAE HWA PHARM Co., Ltd. has an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.